Navigation Links
Manchester's 'first step' to perfect drug combinations

The researchers found a way of identifying ideal drug combinations from billions of others which would prevent inflammation from occurring.

The findings, published in Nature Chemical Biology, could be the first step in the development of new drug combinations to combat severe diseases and conditions.

Most non-infectious disease, such as cancer, stroke and Alzheimer's are worsened by inflammation, which is the body's natural defence mechanism.

Inflammation has evolved to help fight infection but can also be very damaging in long term disease, prolonging suffering and ultimately risking premature death.

After a stroke, the body reacts to the injury as if it were an infection, causing further damage. By blocking the inflammation, the chances of survival or higher quality of life following a stroke are thus greatly enhanced. This can be achieved by quickly and effectively identifying combinations of drugs which can be used together.

Existing 'clot-busting' stroke drugs are only effective if administered within three hours after the stroke often very difficult to achieve as people are often unaware they are having a stroke and even then do not completely solve the problem, often leaving sufferers with serious disabilities.

However, using ideal drug combinations the researchers suggest they can block inflammation and therefore greatly reduce the damage caused by non-communicable diseases such as stroke.

Although the researchers have initially concentrated on stroke, they believe the process can be applied to all drugs and for a huge variety of diseases.

The multi-disciplinary team of researchers, led by Professor Douglas Kell, Professor of Bioanalytical Science at The University of Manchester, developed an evolutionary computer programme which rapidly sifted through nine billion different combinations of potential drugs.

Sorting and testing 50 drug combinations at a time using robotics in the laboratory, the scientists were able to find effective combinations and then refine them as many times as necessary to find ideal combinations.

Ultimately, they hope this will lead to the development of tailored therapies for treating inflammation.

Professor Kell, who is also Chief Executive of the Biotechnology and Biological Sciences Research Council, said: "Most diseases have complex causes. This makes their analysis a problem of systems biology, and to find novel therapies multiple targets need to be attacked at once.

"We have devised a strategy, based on Darwinian evolution, to make this considerably easier. Although our immediate interest is inflammation and conditions such as stroke, our approach is universal and is thus applicable to all complex diseases."

Another advantage of choosing ideal drug combinations is that it allows patients to take smaller doses, which reduces potential toxicology concerns.

Professor Kell and his team worked with computer scientists at the University to create the programme. Professor Pedro Mendes explains: "Our experiments were guided by software that is based on an evolutionary algorithm. The algorithm suggests new drug combinations from previous ones by re-mixing their components much like the DNA of a child is a mix of that of their parents.

"The new drug combinations are then tested and the best are selected to continue generating new ones. In each experiment we tested 50 drug combinations, then the software would tell us which new ones to test in the next experiment."


Contact: Daniel Cochlin
University of Manchester

Related biology news :

1. Researchers generate first complete 3-D structures of bacterial chromosome
2. National Science Foundation makes first awards in Sustainability Research Coordination Program
3. The Worlds First Non Optical FBI Appendix F Certified Fingerprint Sensor
4. First genome-wide association study for dengue identifies candidate susceptibility genes
5. Scientists first to characterize barley plant-stem rust spore communication
6. Angel investor market stabilizes in first half of 2011, UNH Center for Venture Research finds
7. Uncharted territory: Scientists sequence the first carbohydrate biopolymer
8. Worms among first animals to surface after K-T extinction event, CU-led study finds
9. In bubble-rafting snails, the eggs came first
10. First NIH-funded personalized drug development center in US will focus on muscle disease
11. Pumice proposed as home to the first life forms: A new hypothesis in Astrobiology journal
Post Your Comments:
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and ... the "Global Voice Recognition Biometrics Market 2015-2019" ... --> The global voice recognition biometrics ... 2014-2019. --> --> ... has been prepared based on an in-depth market analysis ...
(Date:10/22/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics software ... September 30, 2015.  --> --> ... a decrease of 33% compared to $6.0 million in the same ... was $2.2 million, or $0.10 per diluted share, which compared to ... a year ago.  --> --> ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
(Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
Breaking Biology Technology: